|Bid||290.00 x 300|
|Ask||344.45 x 100|
|Day's Range||285.60 - 294.24|
|52 Week Range||244.28 - 370.57|
|PE Ratio (TTM)||24.56|
|Earnings Date||Apr 23, 2018 - Apr 27, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||381.18|
Yahoo Finance's Jared Blikre breaks down Chipotle technicals for a long play after the stock gapped up following news that current Taco Bell CEO Brian Niccol is being tapped to become the Tex-Mex chain's new chief executive officer.
Ionis Pharmaceuticals (IONS) earns $70 million in milestone and license payments from several drug companies. Spinraza witnesses strong fourth quarter as announced by Biogen in its earnings release.
Biogen’s chief executive said investors overreacted when they pushed down the company’s share price nearly 7% on news that it was adding patients to trials of an Alzheimer’s disease drug.
TOKYO—Biogen Inc.’s chief executive said investors overreacted when they pushed down the company’s share price nearly 7% on news that it was adding patients to trials of an Alzheimer’s disease drug. “It’s very common that we have to increase the sample size, and we don’t take that as a sign that influences whatsoever the outcome of the study,” said Michel Vounatsos, head of the Cambridge, Mass., drugmaker, in an interview on a visit to Japan, where Biogen is trying to expand its presence. A chunk of Biogen’s $62 billion market capitalization is tied to expectations for its Alzheimer’s drug aducanumab, currently in final-stage human trials.
Because of variability on the clinical trial’s primary endpoint, the company increased the sample size for two ongoing trials. Though it rattled investors, some on Wall Street say it could be a good sign....
Biogen Inc (NASDAQ:BIIB) outperformed the Biotechnology industry on the basis of its ROE – producing a higher 21.19% relative to the peer average of 16.36% over the past 12 months.Read More...
Biogen Inc (NASDAQ: BIIB ) tumbled 8 percent Wednesday after announcing a cohort expansion for its aducanumab Alzheimer’s trials — a change certain to delay results. The news, coupled with expected sales ...
FDA's proposed guidelines come in a week when major disappointments in the field were announced by companies developing drugs to treat Alzheimer's.
U.S. regulators have proposed lowering the bar for clinical trial success for experimental Alzheimer's drugs to better align with the current emphasis on the need to treat people when they are in the earliest stages of the brain-wasting disease. Medicines tested to treat Alzheimer's have had a dismal track record, and the Food and Drug Administration has recognized that goals for clinical trials need to evolve to assess drugs aimed at earlier-stage patients. In proposed new guidelines released on Thursday, the FDA appears open to trial goals that better match early patient populations, including people who have yet to display memory loss or functional impairment, such as the ability to wash or dress themselves or cook meals.
Investors are likely to push for Biogen to make an acquisition after worries regarding its chances in Alzheimer's disease sent shares into a tailspin this week, analysts said Thursday.
Alkermes (ALKS) tops earnings and sales estimates in the fourth quarter of 2017 on the back of strong growth of Vivitrol and Aristada. The company provided a decent outlook for 2018.
Biogen said Wednesday that it will increase the size of trials of its experimental Alzheimer’s drug after early data showed “variability” in the data, sending shares of the Cambridge company down sharply. A spokesperson for Biogen (BIIB) said the company had decided to increase the sample size of two closely watched trials by 510 patients, to a total of 3,210 patients, confirming remarks by the company’s chief medical officer during a healthcare conference earlier on Wednesday afternoon. The decision was reached after Biogen conducted a pre-planned, blinded review of the data, which showed “variability in the primary endpoint that was greater than the study protocol assumed,” the spokesperson said, referring to the primary goal of the studies.
Biogen and Ionis Pharmaceuticals, Inc. announced end of study results from CHERISH, the Phase 3 study evaluating SPINRAZA® for the treatment of individuals with later-onset spinal muscular atrophy , were published today in The New England Journal of Medicine.
Analysts weren't surprised Wednesday after Dow's Merck terminated a late-stage study of a potential Alzheimer's disease drug.
Merck (MRK) stalls a phase III study evaluating verubecestat for the treatment of prodromal Alzheimer's disease on the recommendation of an external data monitoring committee.